Brand name – Mozifor
Generic name – Plerixafor
Manufacturer – Hetero Drugs Ltd
Salt composition – Plerixafor (24mg)
Storage – Store at room temperature (10-30°C)
Dosage form – Injection
Strength – 1.2 ml
Packaging – Vial
Gender – Unisex
Indication – Used in the treatment of Multiple myeloma, Non-Hodgkin’s lymphoma and other related conditions
Mozifor injection is used in the treatment of Multiple myeloma, non-Hodgkin’s lymphoma, and other related conditions. It is used in Autologous stem cell transplants. In this procedure, certain blood cells are removed from the body and then returned to the body after chemotherapy and radiation in patients with certain types of cancers.
Plerixafor is a hematopoietic stem cell mobilizer. It works by moving certain blood cells from the bone marrow to the blood so that those cells can be removed for transplant. Plerixafor is an inhibitor of the CXCR4 chemokine receptor. It blocks the binding of its cognate ligand, stromal cell-derived factor-1α (SDF-1α). SDF-1α & CXCR4 play a role in the trafficking & homing of human hematopoietic stem cells (HSCs) to the marrow compartment. Once in the marrow, stem cell CXCR4 can work to help anchor these cells to the marrow matrix, either directly via SDF-1α or through the induction of other adhesion molecules. Treatment with Plerixafor resulted in leukocytosis and elevations in circulating hematopoietic progenitor cells in humans. CD34+ cells mobilized by Plerixafor are capable of engraftment with a long-term repopulating capacity of up to one year in canine transplantation models.
Data on the fold increase in peripheral blood CD34+ cell count (cells/mcL) by apheresis day was evaluated in two placebo-controlled clinical studies in patients with NHL and MM. The fold increase in CD34+ cell count (cells/mcL) over the 24-hour period starting from the day prior to the first apheresis and ending the next morning just before the first apheresis was noted. During this 24-hour period, a single dose of placebo was administered 10 to 11 hours prior to apheresis.
Peak mobilization of CD34+ cells was observed between 6 and 9 hours after administration. A sustained elevation in the peripheral blood CD34+ count was observed from 4 to 18 hours after plerixafor administration with a peak CD34+ count between 10 and 14 hours.
The active ingredient in Mozifor is Plerixafor.
Usage Of Mozifor (Plerixafor)
Mozifor injection is used in the treatment of Multiple myeloma, non-Hodgkin’s lymphoma, and other related conditions. It is used in Autologous stem cell transplants.
- Celrixafor Injection
- Plerimob 24mg Injection